Single Drug Could Turn The Tide; Elan Corp.; Dublin, Ireland elan.com.(HEALTH & MEDICINE)(UNDER THE MICROSCOPE)

Publication: Investor's Business Daily

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2004 Investor's Business Daily, Inc.

Byline: Peter Benesh

It all comes down to this for Elan: After years of losses, plus regulatory and legal woes, the company needs its new multiple sclerosis drug, Antegren, to be a blockbuster.

Elan should know by Nov. 25 if the Food and Drug Administration will approve it. Analyst Ian Sanderson of SG Cowen Securities says approval hinges only on routine labeling negotiations.

There's a lot at stake. The market for MS drugs is $4.2 billion, equally split...

Read the full article for free courtesy of your local library.